Complexity and challenges in defining myeloid-derived suppressor cells - PubMed (original) (raw)
Review
Complexity and challenges in defining myeloid-derived suppressor cells
Vera Damuzzo et al. Cytometry B Clin Cytom. 2015 Mar.
Abstract
Study of myeloid cells endowed with suppressive activity is an active field of research which has particular importance in cancer, in view of the negative regulatory capacity of these cells to the host's immune response. The expansion of these cells, called myeloid-derived suppressor cells (MDSCs), has been documented in many models of tumor-bearing mice and in patients with tumors of various origin, and their presence is associated with disease progression and reduced survival. For this reason, monitoring this type of cell expansion is of clinical importance, and flow cytometry is the technique of choice for their identification. Over the years, it has been demonstrated that MDSCs comprise a group of immature myeloid cells belonging both to monocytic and granulocytic lineages, with several stages of differentiation; their occurrence depends on tumor-derived soluble factors, which guide their expansion and determine their block of differentiation. Because of their heterogeneous composition, accurate phenotyping of these cells requires a multicolor approach, so that the expansion of all MDSC subsets can be appreciated. This review article focuses on identifying MDSCs and discusses problems associated with phenotyping circulating and tumor-associated MDSCs in humans and in mouse models.
Keywords: MDSC; immune suppression; immunology; immunophenotyping; oncology.
© 2014 International Clinical Cytometry Society.
Figures
Figure 1
Subsets of mouse MDSCs. Dot plots showing distribution of Mo-MDSCs (Ly6ChighLY6G−) and PMN-MDSCs (LY6CintLY6G+) found in bone marrow (A), blood (B), spleen (C), lymph nodes (D), and tumor mass (E) of mice challenged with MCA203 fibrosarcoma. Comparison with MDSCs found in tumor mass of mice bearing MN/MCA1 osteosarcoma shown in (F). Analysis performed on CD11b+ cells, after exclusion of cell doublets and dead cells.
Figure 2
Main subsets of human MDSCs. PBMCs from healthy donors stained with 8-color panel to identify the seven main subsets of circulating human MDSCs (A–G). A morphological gate including mononuclear cells (based on FSC and SSC properties) and exclusion of doublets (based on SSC-A vs. SSC-H and FSC-A vs. FSC-H parameters) and dead cells (cells negative for the Live/Dead dye) were applied before gating for MDSC subsets. Figure shows three subsets of monocytic MDSCs: CD14+/IL4Rα+ (A) (28), CD14+/HLA-DRlow/− (C) (56), CD15−/CD14+/CD33high/HLA-DRlow/− (F) (66); three of granulocytic MDSCs: CD15+/IL4Rα+ (B) (28), CD14−/CD15+/CD11b+ (D) (51), CD15high/FSClow/SSChigh (E) (50) and one of immature MDSC: Lin−/HLA-DR− /CD33+/CD11b+ (G) (61,63).
Similar articles
- Complexity and challenges in defining myeloid-derived suppressor cells.
Damuzzo V, Pinton L, Desantis G, Solito S, Marigo I, Bronte V, Mandruzzato S. Damuzzo V, et al. Cytometry B Clin Cytom. 2014 Nov 26. doi: 10.1002/cytob.21206. Online ahead of print. Cytometry B Clin Cytom. 2014. PMID: 25425222 - CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients.
Dubinski D, Wölfer J, Hasselblatt M, Schneider-Hohendorf T, Bogdahn U, Stummer W, Wiendl H, Grauer OM. Dubinski D, et al. Neuro Oncol. 2016 Jun;18(6):807-18. doi: 10.1093/neuonc/nov280. Epub 2015 Nov 17. Neuro Oncol. 2016. PMID: 26578623 Free PMC article. - CD38-Expressing Myeloid-Derived Suppressor Cells Promote Tumor Growth in a Murine Model of Esophageal Cancer.
Karakasheva TA, Waldron TJ, Eruslanov E, Kim SB, Lee JS, O'Brien S, Hicks PD, Basu D, Singhal S, Malavasi F, Rustgi AK. Karakasheva TA, et al. Cancer Res. 2015 Oct 1;75(19):4074-85. doi: 10.1158/0008-5472.CAN-14-3639. Epub 2015 Aug 20. Cancer Res. 2015. PMID: 26294209 Free PMC article. - Myeloid-derived suppressor cells as effectors of immune suppression in cancer.
Pyzer AR, Cole L, Rosenblatt J, Avigan DE. Pyzer AR, et al. Int J Cancer. 2016 Nov 1;139(9):1915-26. doi: 10.1002/ijc.30232. Epub 2016 Jul 12. Int J Cancer. 2016. PMID: 27299510 Review. - Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer.
Albeituni SH, Ding C, Yan J. Albeituni SH, et al. Cancer J. 2013 Nov-Dec;19(6):490-501. doi: 10.1097/PPO.0000000000000006. Cancer J. 2013. PMID: 24270348 Free PMC article. Review.
Cited by
- Potential Association of Maker Expression of Low-Density Neutrophils and Their Phenotypes in Patients with Periodontitis: Control Study.
Mousa AO, Al Hussaini AHA. Mousa AO, et al. Biomed Res Int. 2024 Jun 6;2024:5498307. doi: 10.1155/2024/5498307. eCollection 2024. Biomed Res Int. 2024. PMID: 39376254 Free PMC article. - Multi-Drug Resistance and Breast Cancer Progression via Toll-Like Receptors (TLRs) Signaling.
Pallathadka H, Khaleel AQ, Zwamel AH, Malathi H, Sharma S, Rizaev JA, Mustafa YF, Pramanik A, Shuhata Alubiady MH, Jawad MA. Pallathadka H, et al. Cell Biochem Biophys. 2024 Aug 7. doi: 10.1007/s12013-024-01418-2. Online ahead of print. Cell Biochem Biophys. 2024. PMID: 39110298 Review. - Differential tumor immune microenvironment coupled with tumor progression or tumor eradication in HPV-antigen expressing squamous cell carcinoma (SCC) models.
Shivarudrappa AH, John J, Vashisht M, Ge H, Liu S, Chen J, Siddoway K, Dong R, Chen Z, Wang JH. Shivarudrappa AH, et al. Front Immunol. 2024 Jul 11;15:1405318. doi: 10.3389/fimmu.2024.1405318. eCollection 2024. Front Immunol. 2024. PMID: 39055715 Free PMC article. - Neutrophils in glioma microenvironment: from immune function to immunotherapy.
Sun C, Wang S, Ma Z, Zhou J, Ding Z, Yuan G, Pan Y. Sun C, et al. Front Immunol. 2024 May 8;15:1393173. doi: 10.3389/fimmu.2024.1393173. eCollection 2024. Front Immunol. 2024. PMID: 38779679 Free PMC article. Review. - Neutrophils in Cancer immunotherapy: friends or foes?
Huang X, Nepovimova E, Adam V, Sivak L, Heger Z, Valko M, Wu Q, Kuca K. Huang X, et al. Mol Cancer. 2024 May 18;23(1):107. doi: 10.1186/s12943-024-02004-z. Mol Cancer. 2024. PMID: 38760815 Free PMC article. Review.
References
- Solito S, Pinton L, Damuzzo V, Mandruzzato S. Highlights on molecular mechanisms of MDSC-mediated immune suppression: Paving the way for new working hypotheses. Immunol Invest. 2012;41:722–737. - PubMed
- Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol. 2004;172:989–999. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources